Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Abaloparatide

Mini-review, 106 - 109
doi: 10.11138/ccmbm/2016.13.2.106
Tag this article
Abstract
Full text PDF
Abaloparatide is an investigational analog of human PTHrP (1-34) being developed for the treatment of osteoporosis.
The amino-acid sequence of abaloparatide is identical to that of PTHrP in the first 20 amino-acids, while over half of the remaining amino-acids are different. Some studies in animals and in humans reported that abaloparatide presented a potent anabolic activity with reduced effects on bone resorption as compared to that observed with teriparatide.
This may be due to a more transient signaling response of abaloparatide related to differing affinities of the two drugs to the specific conformations of the PTH1 receptor. In the ACTIVE study, a phase 3 fracture prevention trial, 2460 postmenopausal osteoporotic women at high risk for fracture were randomized to receive 18-months of either daily abaloparatide 80 μg s.c., placebo or teriparatide 20 μg s.c. The reduction in vertebral fracture rate with respect to placebo was 86% in the abaloparatide group and 80% in the teriparatide group. Abaloparatide also produced a significant 43% reduction in the rate of nonvertebral fractures (2.7 vs 4.0% with placebo, p=0.04) whereas teriparatide determined a 28% reduction (2.9 vs 4.0% with placebo, p=NS).
Abaloparatide or teriparatide showed similar increases in BMD at lumbar spine, while the patients of the abalo - paratide group showed significantly greater increases in BMD at both total hip (4.18 vs 3.26%) and femoral neck (3.60 vs 2.66%). Therefore, if the preliminary data of the ACTIVE study is confirmed, abaloparatide may become an important option for the anabolic treatment of postmenopausal osteoporosis.

Vol. XIII (No. 2) 2016 May-August

  1. From the Editor-in-Chief
    Brandi M.L.
  2. Calcio, vitamina D e fratture: domande e risposte
    Brandi M.L.
    doi: 10.11138/ccmbm/2016.13.2.081
  3. Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids
    Vellucci R., Mattia C., Celidonio L., Mediati R.D.
    doi: 10.11138/ccmbm/2016.13.2.089
  4. The role of drugs in bone pain
    Marras F., Tranquilli Leali P.
    doi: 10.11138/ccmbm/2016.13.2.093
  5. Bone pain mechanism in osteoporosis: a narrative review
    Mattia C., Coluzzi F., Celidonio L., Vellucci R.
    doi: 10.11138/ccmbm/2016.13.2.097
  6. Bone healing in 2016
    Buza III J.A., Einhorn T.
    doi: 10.11138/ccmbm/2016.13.2.101
  7. Abaloparatide
    Gonnelli S., Caffarelli C.
    doi: 10.11138/ccmbm/2016.13.2.106
  8. Hereditary Multiple Exostoses: a review of clinical appearance and metabolic pattern
    Beltrami G., Ristori G., Scoccianti G., Tamburini A., Capanna R.
    doi: 10.11138/ccmbm/2016.13.2.110
  9. Underdiagnosis of osteoporotic vertebral fractures in patients with fragility fractures: retrospective analysis of over 300 patients
    Bottai V., Giannotti S., Raffaetà G., Mazzantini M., Casella F., De Paola G., Menconi A., Falossi F., Guido G.
    doi: 10.11138/ccmbm/2016.13.2.119
  10. Risk factors of mortality during the first year after low energy osteoporosis fracture: a retrospective case-control study
    Lloret A., Coiffier G., Couchouron T., Perdriger A., Guggenbuhl P.
    doi: 10.11138/ccmbm/2016.13.2.123
  11. Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database
    Iolascon G., Gimigliano F., Moretti A., Riccio I., Di Gennaro M., Illario M., Monetti V.M., Orlando V., Menditto E.
    doi: 10.11138/ccmbm/2016.13.2.127
  12. Hyaluronic acid in the management of osteoarthritis: injection therapies innovations
    Santilli V., Paoloni M., Mangone M., Alviti F., Bernetti A.
    doi: 10.11138/ccmbm/2016.13.2.131
  13. The use of routine non density calibrated clinical computed tomography data as a potentially useful screening tool for identifying patients with osteoporosis
    Burke C.J., Didolkar M.M., Barnhart H.X., Vinson E.N.
    doi: 10.11138/ccmbm/2016.13.2.135
  14. Evaluation of the bone mineral density of the subjects with avascular necrosis of hip joint
    Taghi Karimi M., Mousavi Nodoshan S.M.
    doi: 10.11138/ccmbm/2016.13.2.141
  15. Densitometric evaluation of bone-prosthetic counterface in hip and knee arthroplasty with modern implants
    Cozzi Lepri A., Giorgini M., Signorini C., Carulli C., Civinini R., Brandi M.L., Innocenti M.
    doi: 10.11138/ccmbm/2016.13.2.144
  16. Low-energy trauma-induced intercondylar femoral fracture
    Aeby M., Wyss T., Mentrup B., Kunstmann E., Jakob F., Aeberli D.
    doi: 10.11138/ccmbm/2016.13.2.151
  17. Early onset acute tubular necrosis following single infusion of zoledronate
    Yachoui R.
    doi: 10.11138/ccmbm/2016.13.2.154
  18. Concomitant extraspinal hyperostosis and osteoporosis in a patient with congenital ichthyosis
    Torkamani N., Phal P., Savarirayan R., Simm P., Varigos G., Wark J.
    doi: 10.11138/ccmbm/2016.13.2.157
Last Viewed articles: la lista degli ultimi x visitati.
  1. Abaloparatide
    Gonnelli S., Caffarelli C.
    doi: 10.11138/ccmbm/2016.13.2.106
credits